Biogen Inc Cmn (BIIB) 260.32 $BIIB
After Yesterday's Rally of 2.28% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Mar 31, 12:17PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $254.19 to a high of $260.00. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $257.92 on volume of 456,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 260.32 (+6.14)
Watch for Biogen Idec to Potentially Pullback After Gaining 2.28% Yesterday
Comtex SmarTrend(R) - Thu Mar 31, 12:16PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $254.19 to a high of $260.00. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $257.92 on volume of 456,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 260.32 (+6.14)
Five Prime Therapeutics Carves Out Tighter Base
at Investor's Business Daily - Wed Mar 30, 5:39PM CDT
Around the turn of the millennium, the Human Genome Project, with all its potential therapies, was a big factor of huge moves in biotech stocks. But what about the extracellular proteome, or the immunome? Five Prime Therapeutics (FPRX) has a library...
BIIB: 260.32 (+6.14), GILD: 91.86 (-0.11), BMY: 63.88 (+0.44), CELG: 100.09 (+1.29), FPRX: 40.63 (+0.79)
Can Biotechnology Company Biogen Beat the Industry's Patent Woes?
at The Street - Wed Mar 30, 9:58AM CDT
After a year of less-than-stellar results, the drug maker is facing even more headwinds. Is all lost for 2016?
BIIB: 260.32 (+6.14)
Stock Market News for March 30, 2016
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 9:10AM CDT
Benchmarks finished in the green on Tuesday after Fed Chairwoman Janet Yellen indicated that the Fed will take a cautious stance before hiking interest rates.
BIIB: 260.32 (+6.14), V: 76.48 (-0.30), FB: 114.10 (-0.60), ALXN: 139.22 (+4.40), ILMN: 162.11 (+4.68), MYL: 46.35 (-0.05), GOOGL: 762.90 (-5.44), MSFT: 55.23 (+0.18), VZ: 54.08 (+0.04), AAPL: 108.99 (-0.57), CELG: 100.09 (+1.29)
Biogen Appoints Michel Vounatsos Executive Vice President, Chief Commercial Officer
BusinessWire - Wed Mar 30, 7:00AM CDT
Biogen (NASDAQ: BIIB) today announced the appointment of Michel Vounatsos as executive vice president and chief commercial officer, effective April 18, 2016.
BIIB: 260.32 (+6.14)
Biogen (BIIB) Stock Price Target Cut at Leerink
at The Street - Mon Mar 28, 3:09PM CDT
Biogen (BIIB) stock price target was lowered at Leerink, which said drug Nusinersen has ‘real opportunity,’ but this is still not enough to offset other risks.
BIIB: 260.32 (+6.14)
Biogen to Present at the Goldman Sachs Alzheimer's Symposium
BusinessWire - Mon Mar 28, 3:01PM CDT
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Goldman Sachs Alzheimer's Symposium. The webcast will be live on Monday, April 11, 2016 at 12:20p.m. ET. To access the live webcast, please visit Biogen's Investors section at www.biogen.com/investors. An archived version of the webcast will be available for 14 days following the presentation.
BIIB: 260.32 (+6.14)
9 Things You Need to Know About Biosimilar Drugs
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 28, 1:59PM CDT
It's not often that investors get an opportunity to invest in a whole new class of drugs, but they've got an opportunity to invest on the ground floor with biosimilars. Last year, the Food and Drug Administration approved the first biosimilar drug, ...
BIIB: 260.32 (+6.14), MYL: 46.35 (-0.05), AMGN: 149.93 (+0.45), TEVA: 53.51 (-0.89), MNTA: 9.24 (+0.33), NVS: 72.44 (-0.11)
The Zacks Analyst Blog Highlights: Gilead, Amgen, Regeneron, Ionis and Biogen
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead, Amgen, Regeneron, Ionis and Biogen
BIIB: 260.32 (+6.14), GILD: 91.86 (-0.11), AMGN: 149.93 (+0.45), IONS: 40.50 (+1.87), REGN: 360.44 (+0.76)
This Biotech Has Gone from Wall St. Darling to Distressed Equity
at The Street - Mon Mar 28, 7:56AM CDT
Biotechnology tends to be a risky sector, but Biogen's stock in particular should be avoided. Here is why its low valuation is a dangerous temptation.
BIIB: 260.32 (+6.14)
Krispy Is Kremed; RIP Andy Grove; Biotechs in No-Man's Land: Jim Cramer's Best Blogs
at The Street - Fri Mar 25, 8:00PM CDT
Cramer dissects Krispy Kreme, honors a tech pioneer and laments the state of biotech stocks.
BIIB: 260.32 (+6.14), VRX: 26.30 (-0.77), WMT: 68.49 (-0.31), INTC: 32.35 (-0.36), SHLD: 15.31 (+0.19), AGN: 268.03 (-6.91), SBUX: 59.70 (-0.31), JACK: 63.87 (-0.59), JNJ: 108.20 (-0.78), DNKN: 47.17 (+0.19), IBM: 151.45 (+3.04), CMG: 470.97 (+4.82), ABBV: 57.12 (+0.12), SNY: 40.16 (-0.53), KKD: 15.59 (+0.16), REGN: 360.44 (+0.76), HD: 133.43 (+0.01), PFE: 29.64 (-0.43), LLY: 72.01 (+0.23), GSK: 40.55 (-0.15), BMY: 63.88 (+0.44), PLKI: 52.06 (+0.28), DIN: 93.43 (-0.91), CELG: 100.09 (+1.29), QSR: 38.83 (-0.50), GILD: 91.86 (-0.11), MRK: 52.91 (-0.31), AZN: 28.16 (-0.16), MCD: 125.68 (-0.15), WEN: 10.89 (+0.03)
Gilead, Biogen Troubles Remind Investors Why Strong Drug Patents Are Vital
at The Street - Fri Mar 25, 9:30AM CDT
A flurry of patent infringement lawsuits and decisions are affecting some of the biotech sector's largest companies.
BIIB: 260.32 (+6.14), GILD: 91.86 (-0.11), EDIT: 34.54 (+3.35), MRK: 52.91 (-0.31), AMGN: 149.93 (+0.45), IONS: 40.50 (+1.87), REGN: 360.44 (+0.76)
Gilead & Biogen's Patent Woes, Amgen Scores Win in Patent Litigation
Arpita Dutt - Zacks Investment Research - Thu Mar 24, 2:15PM CDT
It was all about patent infringement lawsuits this week in the biotech sector with a couple of high profile jury rulings taking center-stage.
BIIB: 260.32 (+6.14), BMRN: 82.48 (+4.38), KITE: 45.91 (+1.69), GILD: 91.86 (-0.11), AMGN: 149.93 (+0.45), IONS: 40.50 (+1.87), REGN: 360.44 (+0.76)
AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:25AM CDT
AVEO Pharmaceuticals (AVEO) struck an exclusive collaboration and license agreement granting CANbridge Life Sciences rights to AV-203 outside North America.
BIIB: 260.32 (+6.14), OPHT: 42.27 (+1.27), AVEO: 0.92 (-0.02), NVS: 72.44 (-0.11)
After Yesterday's Rally of 1.46% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Mar 22, 12:05PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $252.20 to a high of $260.99. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $257.41 on volume of 755,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 260.32 (+6.14)
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 1.46%
Comtex SmarTrend(R) - Tue Mar 22, 12:03PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $252.20 to a high of $260.99. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $257.41 on volume of 755,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 260.32 (+6.14)
Cramer: The Biotech Stocks Are in No Man's Land Right Now
at The Street - Tue Mar 22, 5:17AM CDT
The group rallied yesterday, but it's still not out of the woods.
AGN: 268.03 (-6.91), BIIB: 260.32 (+6.14), VRX: 26.30 (-0.77), BMY: 63.88 (+0.44), CELG: 100.09 (+1.29)
Biogen to Report First Quarter 2016 Financial Results on April 21, 2016
BusinessWire - Mon Mar 21, 3:01PM CDT
Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2016 financial results on Thursday, April 21, 2016, before the financial markets open.
BIIB: 260.32 (+6.14)
After Yesterday's Rally of 2.28% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Mar 31, 12:17PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $254.19 to a high of $260.00. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $257.92 on volume of 456,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 260.32 (+6.14)
Watch for Biogen Idec to Potentially Pullback After Gaining 2.28% Yesterday
Comtex SmarTrend(R) - Thu Mar 31, 12:16PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $254.19 to a high of $260.00. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $257.92 on volume of 456,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 260.32 (+6.14)
Five Prime Therapeutics Carves Out Tighter Base
at Investor's Business Daily - Wed Mar 30, 5:39PM CDT
Around the turn of the millennium, the Human Genome Project, with all its potential therapies, was a big factor of huge moves in biotech stocks. But what about the extracellular proteome, or the immunome? Five Prime Therapeutics (FPRX) has a library...
BIIB: 260.32 (+6.14), GILD: 91.86 (-0.11), BMY: 63.88 (+0.44), CELG: 100.09 (+1.29), FPRX: 40.63 (+0.79)
Can Biotechnology Company Biogen Beat the Industry's Patent Woes?
at The Street - Wed Mar 30, 9:58AM CDT
After a year of less-than-stellar results, the drug maker is facing even more headwinds. Is all lost for 2016?
BIIB: 260.32 (+6.14)
Stock Market News for March 30, 2016
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 9:10AM CDT
Benchmarks finished in the green on Tuesday after Fed Chairwoman Janet Yellen indicated that the Fed will take a cautious stance before hiking interest rates.
BIIB: 260.32 (+6.14), V: 76.48 (-0.30), FB: 114.10 (-0.60), ALXN: 139.22 (+4.40), ILMN: 162.11 (+4.68), MYL: 46.35 (-0.05), GOOGL: 762.90 (-5.44), MSFT: 55.23 (+0.18), VZ: 54.08 (+0.04), AAPL: 108.99 (-0.57), CELG: 100.09 (+1.29)
Biogen Appoints Michel Vounatsos Executive Vice President, Chief Commercial Officer
BusinessWire - Wed Mar 30, 7:00AM CDT
Biogen (NASDAQ: BIIB) today announced the appointment of Michel Vounatsos as executive vice president and chief commercial officer, effective April 18, 2016.
BIIB: 260.32 (+6.14)
Biogen (BIIB) Stock Price Target Cut at Leerink
at The Street - Mon Mar 28, 3:09PM CDT
Biogen (BIIB) stock price target was lowered at Leerink, which said drug Nusinersen has ‘real opportunity,’ but this is still not enough to offset other risks.
BIIB: 260.32 (+6.14)
Biogen to Present at the Goldman Sachs Alzheimer's Symposium
BusinessWire - Mon Mar 28, 3:01PM CDT
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Goldman Sachs Alzheimer's Symposium. The webcast will be live on Monday, April 11, 2016 at 12:20p.m. ET. To access the live webcast, please visit Biogen's Investors section at www.biogen.com/investors. An archived version of the webcast will be available for 14 days following the presentation.
BIIB: 260.32 (+6.14)
9 Things You Need to Know About Biosimilar Drugs
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 28, 1:59PM CDT
It's not often that investors get an opportunity to invest in a whole new class of drugs, but they've got an opportunity to invest on the ground floor with biosimilars. Last year, the Food and Drug Administration approved the first biosimilar drug, ...
BIIB: 260.32 (+6.14), MYL: 46.35 (-0.05), AMGN: 149.93 (+0.45), TEVA: 53.51 (-0.89), MNTA: 9.24 (+0.33), NVS: 72.44 (-0.11)
The Zacks Analyst Blog Highlights: Gilead, Amgen, Regeneron, Ionis and Biogen
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead, Amgen, Regeneron, Ionis and Biogen
BIIB: 260.32 (+6.14), GILD: 91.86 (-0.11), AMGN: 149.93 (+0.45), IONS: 40.50 (+1.87), REGN: 360.44 (+0.76)
This Biotech Has Gone from Wall St. Darling to Distressed Equity
at The Street - Mon Mar 28, 7:56AM CDT
Biotechnology tends to be a risky sector, but Biogen's stock in particular should be avoided. Here is why its low valuation is a dangerous temptation.
BIIB: 260.32 (+6.14)
Krispy Is Kremed; RIP Andy Grove; Biotechs in No-Man's Land: Jim Cramer's Best Blogs
at The Street - Fri Mar 25, 8:00PM CDT
Cramer dissects Krispy Kreme, honors a tech pioneer and laments the state of biotech stocks.
BIIB: 260.32 (+6.14), VRX: 26.30 (-0.77), WMT: 68.49 (-0.31), INTC: 32.35 (-0.36), SHLD: 15.31 (+0.19), AGN: 268.03 (-6.91), SBUX: 59.70 (-0.31), JACK: 63.87 (-0.59), JNJ: 108.20 (-0.78), DNKN: 47.17 (+0.19), IBM: 151.45 (+3.04), CMG: 470.97 (+4.82), ABBV: 57.12 (+0.12), SNY: 40.16 (-0.53), KKD: 15.59 (+0.16), REGN: 360.44 (+0.76), HD: 133.43 (+0.01), PFE: 29.64 (-0.43), LLY: 72.01 (+0.23), GSK: 40.55 (-0.15), BMY: 63.88 (+0.44), PLKI: 52.06 (+0.28), DIN: 93.43 (-0.91), CELG: 100.09 (+1.29), QSR: 38.83 (-0.50), GILD: 91.86 (-0.11), MRK: 52.91 (-0.31), AZN: 28.16 (-0.16), MCD: 125.68 (-0.15), WEN: 10.89 (+0.03)
Gilead, Biogen Troubles Remind Investors Why Strong Drug Patents Are Vital
at The Street - Fri Mar 25, 9:30AM CDT
A flurry of patent infringement lawsuits and decisions are affecting some of the biotech sector's largest companies.
BIIB: 260.32 (+6.14), GILD: 91.86 (-0.11), EDIT: 34.54 (+3.35), MRK: 52.91 (-0.31), AMGN: 149.93 (+0.45), IONS: 40.50 (+1.87), REGN: 360.44 (+0.76)
Gilead & Biogen's Patent Woes, Amgen Scores Win in Patent Litigation
Arpita Dutt - Zacks Investment Research - Thu Mar 24, 2:15PM CDT
It was all about patent infringement lawsuits this week in the biotech sector with a couple of high profile jury rulings taking center-stage.
BIIB: 260.32 (+6.14), BMRN: 82.48 (+4.38), KITE: 45.91 (+1.69), GILD: 91.86 (-0.11), AMGN: 149.93 (+0.45), IONS: 40.50 (+1.87), REGN: 360.44 (+0.76)
AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:25AM CDT
AVEO Pharmaceuticals (AVEO) struck an exclusive collaboration and license agreement granting CANbridge Life Sciences rights to AV-203 outside North America.
BIIB: 260.32 (+6.14), OPHT: 42.27 (+1.27), AVEO: 0.92 (-0.02), NVS: 72.44 (-0.11)
After Yesterday's Rally of 1.46% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Mar 22, 12:05PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $252.20 to a high of $260.99. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $257.41 on volume of 755,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 260.32 (+6.14)
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 1.46%
Comtex SmarTrend(R) - Tue Mar 22, 12:03PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $252.20 to a high of $260.99. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $257.41 on volume of 755,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 260.32 (+6.14)
Cramer: The Biotech Stocks Are in No Man's Land Right Now
at The Street - Tue Mar 22, 5:17AM CDT
The group rallied yesterday, but it's still not out of the woods.
AGN: 268.03 (-6.91), BIIB: 260.32 (+6.14), VRX: 26.30 (-0.77), BMY: 63.88 (+0.44), CELG: 100.09 (+1.29)
Biogen to Report First Quarter 2016 Financial Results on April 21, 2016
BusinessWire - Mon Mar 21, 3:01PM CDT
Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2016 financial results on Thursday, April 21, 2016, before the financial markets open.
BIIB: 260.32 (+6.14)
